One less in the HCV arena. The writing was on the wall when XTLB shifted to the pain arena by purchasing DOVP's molecule.
XTL Biopharma stops developing XTL-2125 for hepatitis C
By Robert Daniel
Last Update: 3:17 AM ET Jun 6, 2007
TEL AVIV (MarketWatch) -- XTL Biopharmaceuticals Ltd., (XTLB) the Rehovot, Israel, drug developer, said it stopped developing XTL-2125, a potential treatment for chronic hepatitis C. In a Phase I trial, XTL said, "HCV-RNA viral load reductions in patients treated with XTL-2125 were not significantly different from those observed in the placebo group." The company has bicifadine, which treats neuropathic pain, "as a lead product in late-stage clinical development," and its XTL-DOS program for hepatitis C is "very promising," Chief Executive Ron Bentsur said in a statement. The company also said it continues its efforts to broaden its product line by licensing and acquiring clinical-stage products.
